Equities analysts expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post ($0.06) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.24). BioDelivery Sciences International reported earnings per share of ($0.16) in the same quarter last year, which suggests a positive year-over-year growth rate of 62.5%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.15) per share for the current fiscal year, with EPS estimates ranging from ($0.37) to ($0.05). For the next year, analysts anticipate that the company will report earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $19.77 million during the quarter, compared to the consensus estimate of $19.60 million. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%.
Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 21st. BidaskClub downgraded shares of Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday, July 13th. Finally, Cantor Fitzgerald set a $8.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $6.20.
Shares of NASDAQ:BDSI traded up $0.04 during trading on Friday, hitting $3.81. 829,500 shares of the company were exchanged, compared to its average volume of 988,305. The stock has a 50 day simple moving average of $4.35. The firm has a market cap of $337.45 million, a P/E ratio of -5.22 and a beta of 0.47. The company has a quick ratio of 2.57, a current ratio of 2.88 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 1-year low of $2.35 and a 1-year high of $5.37.
In related news, CEO Herm Cukier sold 30,285 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $5.07, for a total value of $153,544.95. Following the sale, the chief executive officer now owns 66,666 shares of the company’s stock, valued at $337,996.62. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $4.77, for a total transaction of $38,160.00. Following the completion of the sale, the director now directly owns 598,254 shares in the company, valued at approximately $2,853,671.58. The disclosure for this sale can be found here. In the last three months, insiders sold 2,429,743 shares of company stock worth $11,707,558. 8.94% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the stock. Advisor Group Inc. boosted its position in BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after acquiring an additional 3,943 shares during the last quarter. Geode Capital Management LLC boosted its position in BioDelivery Sciences International by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock valued at $1,915,000 after acquiring an additional 5,628 shares during the last quarter. Raymond James & Associates boosted its position in BioDelivery Sciences International by 14.9% during the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after acquiring an additional 6,000 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in BioDelivery Sciences International by 23.3% during the first quarter. Janney Montgomery Scott LLC now owns 45,800 shares of the specialty pharmaceutical company’s stock valued at $243,000 after acquiring an additional 8,642 shares during the last quarter. Finally, BTR Capital Management Inc. bought a new stake in BioDelivery Sciences International during the second quarter valued at $47,000. 56.72% of the stock is currently owned by institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.